
医学资讯IDH1突变ivosidenib
Ivosidenib单药治疗在IDH1突变骨髓增生异常性肿瘤/综合征中显示出前景:一项2期研究
By MedXY|2026年8月29日
Ivosidenib单药治疗在IDH1突变骨髓增生异常性肿瘤中显示出显著的疗效和安全性,尤其是在初治高危患者中,提示其可能成为新的治疗选择。
Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.